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Extending our previous analyses to the most recently described monoclonal broadly neutralizing antibodies (bNAbs), we con-
firmed a drift of HIV-1 clade B variants over 2 decades toward higher resistance to bNAbs targeting almost all the identified
gp120-neutralizing epitopes. In contrast, the sensitivity to bNAbs targeting the gp41 membrane-proximal external region re-
mained stable, suggesting a selective pressure on gp120 preferentially. Despite this evolution, selected combinations of bNAbs
remain capable of neutralizing efficiently most of the circulating variants.
Despite the ability of HIV-1 to evade the antibody response,some HIV-1-infected individuals develop high titers of
broadly neutralizing antibodies (bNAbs) (1–11). Since 2009,
thanks to the development of single-cell-based antibody cloning
techniques, a large number of monoclonal bNAbs with outstand-
ing potencies have been isolated from such individuals (12–21).
Most of them target a few major sites of vulnerability on HIV-1
Env. Three of these sites are located within the exterior glycopro-
tein gp120: the CD4-binding site (13, 18, 21–23) and two glycan-
dependent epitopes involving the V1/V2 and the V3 loops (16, 19,
20, 24, 25). A fourth site involves the membrane-proximal exter-
nal region (MPER) of the transmembrane gp41 glycoprotein (15).
A few additional sites involve recently defined epitopes at the
gp41-gp120 interface (14, 17, 26). When passively transferred,
these bNAbs can prevent either HIV-1 infection in humanized
mice or simian-human immunodeficiency virus infection in ma-
caques (27, 28). In addition, these bNAbs can also suppress estab-
lished infection in humanized mice and macaques (29–32). The
data strongly support testing the efficacy of bNAbs in human clin-
ical trials. In this context, it is important to define the sensitivity to
neutralization of the most representative HIV-1 variants that
must be targeted. Due to the genetic bottleneck that occurs at
transmission, transmitted variants may possess a selective advan-
tage, and therefore preventive immunoprophylaxis should target
early/transmitted variants. In addition, the rapid evolution of the
HIV-1 species and its adaptation to its new host, the human pop-
ulation, suggests taking into account the most recently spreading
variants, i.e., those that have been isolated at the time of primary
infection during the recent years, as representative(s) of the con-
temporary epidemic.
Based on these hypotheses, we and others reported that HIV-1
appears to become more resistant to antibody neutralization over
the course of the epidemic (33, 34). In our previous study, we
compared the neutralization sensitivity of early/transmitted
HIV-1 variants from patients infected by subtype B viruses at three
periods of the epidemic (1987 to 1991, 1996 to 2000, and 2006 to
2010). A progressively increasing resistance to neutralization was
observed over calendar time, for both human sera and the bNAbs
b12, VRC01, VRC03, NIH45-46G54W, PG9, PG16, PGT121,
PGT128, and PGT145 (33). Since then, bNAbs with increased
potency or targeting different epitopes have been generated, in-
cluding bNAbs improved by structure-based gene modifications
(37–41). Therefore, we extended the analyses to a panel of new
bNAbs described: PG9-iMab, PG16-iMab, 10E8, 3BNC117,
NIH45-46m2, NIH45-46m7, 10-1074, JM4sdAb, 8ANC195, and
PG9-16-RSH (Table 1). This new study provides an updated over-
view of the potency and breadth of these bNAbs against early/
transmitted contemporary HIV-1 variants that could guide the
selection of antibodies to be used in immunoprophylaxis strate-
gies and of epitopes to be considered for vaccine design.
Increasing resistance to bNAbs targeting gp120. The HIV-1
population that we studied was described previously (33). It was
derived from 40 Caucasian men having sex with men (MSM) with
primary infection, infected by clade B viruses at three periods of
the French epidemic: between 1987 and 1991 (historical patients
[HP]), 1996 and 2000 (intermediate patients [IP]), and 2006 and
2010 (contemporary patients [CP]). For each patient, blood sam-
ples were collected shortly after infection (before 3 months postin-
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fection, except for a few cases). Pseudotyped viruses expressing
envelope glycoprotein (Env) variants representative of the viral
quasispecies infecting each patient were generated from the entire
env gene amplified by reverse transcription-PCR from plasma-
extracted viral RNA. Phylogenetic analysis of the env sequences of
these viruses with a large series of env sequences issued from clade
B variants isolated at the time of primary infection from patients
of various geographic origins indicated that our viral population
did not belong to a genetically restricted subset of viruses but
could be considered representative of the entire clade B HIV-1
population worldwide (33). In addition, the genetic diversity
among the env sequences of our viral population increased grad-
ually from HP to CP, suggesting that it mirrors the global genetic
evolution of HIV-1 over the course of the epidemic (33).
The neutralizing activities of bNAbs described in Table 1 were
evaluated by using a luciferase reporter gene assay in TZM-bl cells
based on single-round infection of Env-pseudotyped viruses (33).
Although the recent bNAbs that target the CD4-binding site,
NIH45-46m2, NIH45-46m7 (both derived from NIH45-46G54W),
and 3BNC117 were more potent than the previously tested b12,
VRC01, VRC03, and NIH45-46G54W, we observed still a signifi-
cant decrease in sensitivity to neutralization over the three periods
of the epidemic for all these bNAbs (Fig. 1A). The median 50%
inhibitory concentration (IC50) of NIH45-46m2 increased pro-
gressively and significantly from 0.029 g/ml for HP to 0.098
g/ml for CP (P  0.012). For NIH45-46m7 and 3BNC117, the
median IC50 increased, respectively, from 0.035 and 0.020 g/ml
for HP to 0.098 and 0.270g/ml for IP and remained stable for CP
(0.087 g/ml and 0.175 g/ml, respectively; P 0.013 and 0.017,
respectively).
The modified bNAbs that target the N160-glycan V1V2
epitopes PG9-16-RSH, PG9-iMab, and PG16-iMab were also
more potent than the previously tested PG9, PG16, and PGT145
to neutralize the early/transmitted viruses (Fig. 1B). However, we
still observed a significant decrease in sensitivity to neutralization
over the three periods of the epidemic. The median IC50s of PG9-
16-RSH, PG9-iMab, and PG16-iMab increased progressively
from 0.160, 0.043, and 0.011 g/ml for HP to 2.495, 0.068, and
0.065 g/ml for CP, respectively. This trend was significant for
PG9-16-RSH (P  0.012) and PG16-iMab (P  0.006) and just
above the limit of significance for PG9-iMAb (P  0.084). PG9-
iMab and PG16-iMab are bispecific antibodies that were con-
structed using the humanized anti-CD4 antibody ibalizumab
(iMab) as the scaffold, onto which the antigen-binding domains
of PG9 and PG16 were engrafted (40). Interestingly, the sensitivity
to the parental iMab was similar for HP, IP, and CP (median IC50s
of 1.42, 1.47, and 1.35 g/ml, respectively; P  0.564) (Fig. 1B),
suggesting that the increasing resistance to PG9-iMAb and PG16-
iMAb over the course of the epidemic was specifically due to the
paratope domain of PG9 and PG16.
The potency of the bNAb 10-1074, isolated from the B-cell
lineage encoding PGT121 targeting an N332-glycan V3 epitope
(16), was somewhat similar to that of the previous bNAbs PGT121
and PGT128. Although we also observed a trend for a decreasing
sensitivity to neutralization by these reagents over the three peri-
ods, the phenomenon reached significance only for PGT128 (Fig.
1C). These slight differences could be attributed to modalities of
glycan recognition by these antibodies (16, 20).
As previously reported (33), the sensitivity to neutralization by
2G12 was low, even for viruses from HP, and no trend of increas-
ing resistance to this bNAb was observed (Fig. 1D). The excep-
tional nature of this antibody (42) associated with its low potency
might explain the absence of drift for its targeted epitope. HIV-1
variants from CP were more resistant to the llama-derived anti-
body JM4sdAb than the variants that were transmitted 2 decades
earlier (median IC50s of 1.720, 1.930, and 3.065 g/ml for HP, IP,
and CP, respectively; P  0.002). This bNAb reacts with a CD4-
induced epitope, and this reaction involves elements of both the
coreceptor- and CD4-binding sites (37, 39). Although not signif-
icant, a similar trend was observed for the human bNAb
8ANC195, which targets a newly defined glycan-dependent
epitope adjacent to the CD4-binding site and spanning gp120-
gp41 interface (17). The median IC50 increased progressively from
HP to CP (median IC50s, 0.420, 0.980, and 3.020g/ml for HP, IP,
and CP, respectively; P  0.068) (Fig. 1D). Future works with
other bNAbs belonging to this class should provide additional
information on the drift of this antigenic site which involves both
envelope subunits, gp120 and gp41, and on the selective pressure
that it undergoes.
The more recent bNAb 10E8 that targets the MPER was more
potent than the previously tested MPER bNAbs 2F5 and 4E10.
However, in agreement with our previous observations obtained
with 2F5 and 4E10, no trend of increased resistance to 10E8 over
time was observed (median IC50s, 0.195, 0.300, and 0.190 g/ml
for HP, IP, and CP, respectively; P 0.416) (Fig. 1E).
Altogether, these results fully confirmed our first observations
that indicated an increasing resistance of HIV-1 clade B to bNAbs
targeting the major gp120 epitopes over 2 decades. Interestingly,
drift was observed—not for a single major neutralization region of
gp120, but for almost all the identified neutralization targets eval-
uated. This suggests a continuous selective pressure involving all
epitopes, and therefore a drift of the entire gp120. In contrast, we
observed a constant stable sensitivity to bNAbs targeting the
TABLE 1 Characteristics of the bNAbs tested
Antibody Specificitya Reference
b12 gp120-CD4bs 35
VRC01 gp120-CD4bs 21
VRC03 gp120-CD4bs 21
NIH45-46G54W gp120-CD4bs 13
NIH45-46m2 gp120-CD4bs 38
NIH45-46m7 gp120-CD4bs 38
3BNC117 gp120-CD4bs 18
PGT145 gp120-V1V2 (glycan dependent) 20
PG9 gp120-V1V2 (glycan dependent) 19
PG16 gp120-V1V2 (glycan dependent) 19
PG9-16-RSH gp120-V1V2 (glycan dependent) 41
PG9-iMab Bispecific antibody 40
PG16-iMab Bispecific antibody 40
PGT135 gp120-V3 (glycan dependent) 20
PGT121 gp120-V3 (glycan dependent) 20
PGT128 gp120-V3 (glycan dependent) 20
10-1074 gp120-V3 (glycan dependent) 16
2G12 gp120-N332 dependent 36
8ANC195 g120/gp41 interface 17
JM4sdAb gp120-CD4bs/CoRbs 39
4E10 gp41-MPER 36
2F5 gp41-MPER 36
10E8 gp41-MPER 15
a CD4bs, CD4 binding site; CoRbs, coreceptor binding site.
Resistance to Neutralization of HIV-1 Species
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gp41 MPER, suggesting either a lack of selective pressure, a
weak tolerance to mutations in this region, or a combination of
both. The first possibility, lack of selective pressure, is sup-
ported by the low reported frequency of NAbs elicited to this
region (4). Although anti-MPER antibodies have been detected
in HIV-1-infected individuals, they are associated with the
neutralizing activity of sera only in rare cases (4, 5, 43, 44). The
second possibility is supported by the fact that it is difficult to
select resistant strains in vitro without impairing infectivity
(45). However, exceptional 4E10-resistant HIV-1 isolates with
rare MPER polymorphisms have been described (46). The fact
that mutations within the MPER did not occur during passive
immunization of HIV-1-infected individuals with 2F5 and
4E10 could be a result of both mechanisms (45).
Neutralization potency and breadth of bNAbs against early/
transmittedHIV-1 variants. The neutralizing activities of bNAbs
against our panel of pseudotyped viruses were compared by using
IC50 heat map analysis (Fig. 2A). Only the bispecific antibodies
PG9-iMab and PG16-iMab were able to neutralize all viruses at
less than 1 g/ml. Their neutralization breadth was exceptional
compared to that of the parental PG9 and PG16, or to PG9-16-
RSH (a chimeric derivate of PG9 and PG16). PG9-iMab and
PG16-iMab were also the most potent of all bNAbs tested, with
geometric mean IC50s of 0.047 g/ml and 0.029 g/ml, respec-
tively, which indicate 32-fold and 52-fold higher potency than
iMab (1.51 g/ml) and 56-fold and 42-fold higher potency than
PG9 (2.62 g/ml) and PG16 (1.22 g/ml), respectively (Fig. 2B).
The geometric mean IC50s of PG9-iMab, PG16-iMab, iMab, PG9,
and PG16 observed with our panel of early/transmitted subtype B
viruses were approximately 10-fold higher than those previously
reported with a panel of viral isolates from all major circulating
genetic subtypes derived from patients at various stages of infec-
tion (40). These differences might be due to the fact that the virus
populations were very different. Among all the other bNAbs,
FIG 1 Enhanced resistance of early/transmitted HIV-1 clade B variants to neutralization by monoclonal NAbs (MoNAbs) over the course of the epidemic.
Comparisons are shown for the neutralization sensitivity of Env-pseudotyped viruses derived from historical patients (HP; n 11), intermediate patients (IP;
n 15), and contemporary patients (CP; n 14) by the following groups of antibodies: b12, VRC01, VRC03, and NIH45-46G54W (adapted from reference 33)
and NIH45-46m2, NIH45-46m7, and 3BNC117 (this study) (A); PGT145, PG9, and PG16 (adapted from reference 33) and PG9-16-RSH, PG9-iMab, PG16-
iMab, and iMab (this study) (B); PGT135, PGT121, and PGT128 (adapted from reference 33) and 10-1074 (this study) (C); 2G12 (adapted from reference 33)
and 8ANC195 and JM4sdAb (this study) (D); 4E10 and 2F5 (adapted from reference 33) and 10E8 (this study) (D). Box plots show the distributions of antibody
titers (IC50s) of each bNAb toward pseudotyped viruses of each period; the horizontal lines represent the 10th, median, and 90th percentiles. Each datum point
represents the mean value of the assay performed in duplicate. Differences of neutralization sensitivity between viruses over calendar time were evaluated using
a Jonckheere-Terpstra test.
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FIG 2 Potency and breadth comparison of bNAbs against early/transmitted HIV-1 variants. (A) A heat map of the neutralizing activities (IC50s) of the bNAbs
against a panel of 40 pseudotyped viruses from patients with primary infection (HP, IP, and CP), with increasingly darker colors indicating increasing
neutralization sensitivity, as indicated by the key. (B) Neutralization breadth of bNAbs against the panel of pseudotyped viruses. Percentages of viruses
neutralized for each bNAb at less than 1g/ml are indicated above the graph. IC50s greater than the highest bNAb concentration tested (10g/ml) were assigned
a value of 10 in the geometric mean IC50 calculations.
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NIH45-46m2 and NIH45-46m7, which target the CD4-binding
site, were the broadest and most potent. They neutralized 95% of
viruses at less than 1 g/ml, with a geometric mean IC50s of 0.082
g/ml for NIH45-46m2 and 0.085 g/ml for NIH45-46-m7. The
breadth and potency of 3BNC117 was only slightly lower, neutral-
izing 82.5% of viruses at less than 1 g/ml with a geometric mean
IC50 of 0.097 g/ml. The bNAb 10-1074 was the broadest and
most potent antibody among those targeting the N332-glycan V3
region. It neutralized 80% of the viruses at less than 1g/ml, with
a geometric mean IC50 of 0.106 g/ml, whereas PGT121 and
PGT128 neutralized 70% and 67.5% of the viruses with geometric
mean IC50s of 0.144 g/ml and 0.163 g/ml, respectively. Among
antibodies that do not target the three major epitopes on gp120,
8ANC195 was the broadest and most potent. It neutralized 52.5%
of viruses with a geometric mean IC50 of 1.244 g/ml. (Fig. 2B).
The bNAb 10E8 was the most potent of the anti-MPER reagents,
neutralizing 85% of the viruses at less than 1 g/ml with a geo-
metric mean IC50 of 0.216 g/ml (Fig. 2B).
Neutralization coverage of the most recently transmitted
HIV-1 variants. The perspective of using some bNAbs in human
clinical trials and as tools for vaccine design and the evolution of
the HIV-1 species that we have described necessitate focusing our
attention on early/transmitted viruses collected during the most
recent years of the epidemic. We therefore analyzed the cumula-
tive frequency of neutralization of the viruses from the CP accord-
ing to IC50s of up to 1g/ml, considering the area under the curve
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FIG 3 Neutralization coverage of the most recently transmitted HIV-1 variants. (A) Coverage graph comparing the neutralization breadth and potencies of
bNAbs against pseudotyped viruses from contemporary patients. The y axis shows the cumulative frequency of IC50s up to the concentration shown on the x axis.
(B) Bar graph showing values for the area under the curve for the bNAbs shown in the coverage graph. (C) The neutralization coverage of viruses from
contemporary patients was tested against a 1:1:1 combination of NIH45-46m2, 10-1074, and 10E8. Solid lines show the coverage of each bNAb used alone or in
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coverage that would be obtained if the neutralizing activities of combined antibodies were fully additive. (D) Bar graph showing values for the area under the
curve for the bNAbs used alone or in combination, as shown in the coverage graph.
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for each bNAb (Fig. 3A and B). Besides the bispecific antibodies
PG9-iMab and PG16-iMab, which showed exceptional neutral-
ization coverage, the bNAbs NIH45-46m7, NIH45-46m2, 10-
1074, 3BNC117, NIH45-46G54W, and 10E8 were the most potent
(Fig. 3B). They neutralized between 71% and 86% of viruses at less
than 1 g/ml (Fig. 3A). It would be useful to identify a combina-
tion of bNAbs that would neutralize 100% of HIV-1 variants at a
low concentration, in order to prevent escape of any variant resis-
tant to 1 or 2 of the bNAbs. We therefore selected three of the most
potent bNAbs identified above, each targeting a different epitope,
and investigated the sensitivity of CP variants to neutralization by
a 1:1:1 combination of NIH45-46m2, 10-1074, and 10E8. The
observed neutralization coverage by various concentrations of this
combination was compared to the theoretical coverage that would
be obtained if the neutralizing activities were fully additive (Fig.
3C and D). The NIH45-46m2/10-1074/10E8 combination was
able to neutralize all the contemporary HIV-1 variants with an
IC50 of 0.37 g/ml, reaching approximately the theoretical
curve and the potency of the bispecific antibodies PG9-iMab
(IC50, 0.22 g/ml) and PG16-iMab (IC50, 0.27 g/ml). The
effect of this combination was nearly additive but neither syner-
gistic nor antagonistic. Compared to the NIH45-46G54W/PGT128
combination tested in our previous study, this new combination
was more potent, reaching similar neutralization coverage at ap-
proximately 3-fold-lower bNAb concentrations (33). These re-
sults suggest that optimal neutralization coverage of recently
transmitted variants may be achieved by combining three bNAbs
targeting different epitopes, i.e., the CD4-binding site, the N332-
glycan-dependent V3 epitope, and the MPER.
In conclusion, the data confirm the ongoing adaptation of the
HIV-1 species to the humoral immunity of the human population
over the course of the epidemic, even using the most potent and
broadly neutralizing monoclonal antibodies described to date.
The drift in resistance to neutralization concerns only the external
glycoprotein gp120, but not the MPER. It could suggest a high
selective pressure on gp120, in agreement with the higher fre-
quency of NAbs targeting the gp120 epitopes compared to the low
frequency of NAbs to MPER in sera from elite neutralizers (4).
Interestingly enough, almost all the identified major neutraliza-
tion epitopes of gp120 are affected by this antigenic drift, suggest-
ing that gp120 as a whole has progressively evolved in less than 3
decades. What mechanism has been responsible for this evolu-
tion? Has gp120 been shaped progressively by the neutralizing
responses of the transmitters? It is difficult to privilege this hy-
pothesis if we consider that most transmissions occur during acute
infection, when bNAbs are not yet present in the transmitters, and
that ancestral viruses are preferentially transmitted when trans-
missions occur during long-lasting infections (47, 48). However,
if it were the case, this would suggest that the evolution of sensi-
tivity to neutralization has been driven by rare events of late trans-
mission of isolates, selected under NAb pressure, that might have
an advantage over ancestral viruses. In any case, it remains to be
determined whether the antigenic drift has been associated with
other functional modifications of gp120 properties, such as inter-
actions with the receptor and coreceptors, or cell entry efficacy
more globally. Such a functional drift could be associated with an
increase or, alternatively, a decrease of HIV-1 virulence, a major
question that must be addressed. Despite this evolution, the good
news is that the most recently identified bNAbs, either modified as
bispecific antibodies or associated in combinations selected to tar-
get different epitopes, still remain capable of efficiently neutraliz-
ing the most recently transmitted HIV-1 clade B variants. These
bispecific antibodies or these documented combinations should
be favored for human trials.
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